18 February 2025
18 February 2025
Ono’s therapy Romvimza is administered twice-weekly compared to Daiichi Sankyo’s twice-daily Turalio.
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.
Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in 2025.
The FDA’s designation for the antibody follows positive results from Phase I and II trials.
This is the second such designation for the drug, following a previous status for glioblastoma.
The MoU aims to develop projects that contribute to the advancement of medical science and patient care.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
